Agents that block the effects of IL-1 offer the potential to treat diseases included in chronic inflammatory disorders such as rheumatoid arthritis and Crohn's disease (Hallegua and Weisman, 2002). The gene discussed is IL1B; the disease is rheumatoid arthritis.